

Glass Pharms release their own-brand Cannabis Flower range to the UK market.

Wednesday 31 July, 2024

Glass Pharms, the UK-based medical cannabis cultivation company based at a purpose-built 2.4-hectare facility in Wiltshire, have launched their own-branded range of Cannabis-based products for medicinal use (CBPMs) with a UK pharmaceutical manufacturing partner, which will be available at several pharmacies.

Using cannabis flower grown at the facility, the medicines will offer a range of prescribing options to UK clinicians and patients that have previously been inconsistently available. The initial launch will include a High-CBD flower that contains less than 1% THC, a ratio which according to a recent published study by the University of Colorado Boulder, may be more effective in treating anxiety than other flowers with higher THC content.¹

“As well as producing High-THC Cannabis flower, we have a commitment to bring CBD-containing medical cannabis flower to the UK market as we believe it gives prescribers options for cannabis-naïve patients that would otherwise be missing.” said James Duckenfield, Glass Pharms’ CEO “Careful titration of THC content has been shown to improve the initial patient experience and led to better outcomes for new users of medical cannabis.”

Other flowers that will be available immediately include an entry-level High-THC flower and a high terpene content High-THC flower. More cultivars will become available in the Glass Pharms-branded range over the next few months.

The CBPMs will be manufactured to the new British Pharmacopeia (BP) standard for Cannabis flower which became legally binding in the UK on July 1st of this year, returning Cannabis flower as a medicine to the British Pharmacopeia after it was removed for prohibitionist reasons in 1932, after having been included since the first edition published in 1864.

The flower is non-irradiated and produced to exacting microbial standards in the purpose-built facility, which was specifically designed to produce Cannabis flower to pharmaceutical standards.

Glass Pharms’ ultra-modern facility operates off-grid, powered by food waste that is turned into energy in an adjacent anaerobic digestion plant, giving the cannabis flower grown at the facility a best-in-class sustainability profile.

For more information contact: Mark Heley, External Relations, Glass Pharms

mh@glasspharms.com

07904 856199

1

Acute and Extended Anxiolytic Effects of Cannabidiol in Cannabis Flower: A Quasi-Experimental ad libitum Use Study

<https://www.liebertpub.com/doi/10.1089/can.2023.0187>

Media:



Related Sectors:

Medical & Pharmaceutical ::

Related Keywords:

Medical Cannabis :: Cannabis UK ::

Scan Me:



Company Contact:

Glass Pharms

T. 07904856199

E. mh@glasspharms.com

W. <https://glasspharms.com/>

Additional Contact(s):

Mark Heley is the press contact

View Online

Additional Assets:

Newsroom: Visit our Newsroom for all the latest stories:

<https://www.glasspharms.pressat.co.uk>